Based on the hypothesis that interruption of anti-PD-1/PD-L1 binding may activate T cells against cancer cells, PD-1 blocking antibodies have been developed as immune checkpoint inhibitors for cancer therapy [7] (Fig. 1). The gene discussed is PDCD1; the disease is cancer.